FDA-Cleared, All-in-One Advanced Energy
System Now Available for Medical
Professionals
CLEARWATER,
Fla., Jan. 25, 2023 /PRNewswire/ -- Apyx
Medical Corporation (NASDAQ: APYX) (the "Company"), the
manufacturer of a proprietary helium plasma and radiofrequency
technology marketed and sold as Renuvion®, today
announced the launch of its latest-generation Renuvion generator,
the Apyx One Console, in the United
States.
The Apyx One Console is a multi-functional
generator incorporating an advanced 3-in-1 energy system that
enables plastic and cosmetic surgeons to utilize Renuvion
technology, together with full monopolar and bipolar
energy.
Key features of the Apyx One Console include
adaptive and intuitive touch screens, procedural presets by body
part, cloud connectivity, data sharing and logging, remote upgrade
capabilities and system diagnostics, and an advanced gas system
that measures and monitors gas volume and usage.
Four years in the making, the design,
development, and testing of the Apyx One Console was led by the
Company's product development team, who collaborated with the
following physicians to guide and validate the product design and
usability requirements: Dr. John
Frederick, Dr. Michael
Kluska, Dr. Adam Rubinstein
and Dr. Drew Schnitt.
"We are thrilled to announce the launch of the Apyx One Console,
which is in keeping with our commitment to developing
industry-leading, customer-focused products for use by our
physicians," said Charlie
Goodwin, President, and Chief Executive Officer. "This
next-generation Renuvion generator features a variety of
improvements to enhance the overall user experience and is designed
to support both prior and future generations of our Renuvion
handpieces."
The full system is available to physicians
throughout the U.S. and comes with an industry-leading 4-year
warranty. An upgrade program is available for current Apyx
customers who would like to exchange their current system for the
new Apyx One Console.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy
technology company with a passion for elevating people's lives
through innovative products, including its Helium Plasma Technology
products marketed and sold as Renuvion® in the
cosmetic surgery market and J-Plasma® in the hospital
surgical market. Renuvion® and
J-Plasma® offer surgeons a unique ability to
provide controlled heat to tissue to achieve their desired results.
The Company also leverages its deep expertise and decades of
experience in unique waveforms through OEM agreements with other
medical device manufacturers. For further information about the
Company and its products, please refer to the Apyx Medical
Corporation website at www.ApyxMedical.com.
Cautionary Statement on
Forward-Looking Statements
Certain matters discussed in this release and
oral statements made from time to time by representatives of the
Company may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements, including but not limited to, any statements regarding
the potential impact of the COVID-19 pandemic and the actions by
governments, businesses and individuals in response to the
situation; projections of net revenue, margins, expenses, net
earnings, net earnings per share, or other financial items;
projections or assumptions concerning the possible receipt by the
Company of any regulatory approvals from any government agency or
instrumentality including but not limited to the U.S. Food and Drug
Administration, supply chain disruptions, component shortages,
manufacturing disruptions or logistics challenges; or macroeconomic
or geopolitical matters and the impact of those matters on the
Company's financial performance.
Forward-looking statements and information are
subject to certain risks, trends and uncertainties that could cause
actual results to differ materially from those projected. Many of
these factors are beyond the Company's ability to control or
predict. Important factors that may cause the Company's actual
results to differ materially and that could impact the Company and
the statements contained in this release include but are not
limited to risks, uncertainties and assumptions relating to the
regulatory environment in which the Company is subject to,
including the Company's ability to gain requisite approvals for its
products from the U.S. Food and Drug Administration and other
governmental and regulatory bodies, both domestically and
internationally; the impact of the recent FDA Safety Communication
on our business and operations; factors relating to the effects of
the COVID-19 pandemic; sudden or extreme volatility in commodity
prices and availability, including supply chain disruptions;
changes in general economic, business or demographic conditions or
trends; changes in and effects of the geopolitical environment;
liabilities and costs which the Company may incur from pending or
threatened litigations, claims, disputes or investigations; and
other risks that are described in the Company's Annual Report on
Form 10-K for the fiscal year ended December
31, 2021 and the Company's other filings with the Securities
and Exchange Commission. For forward-looking statements in this
release, the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The Company assumes no obligation to
update or supplement any forward-looking statements whether as a
result of new information, future events or otherwise.
Media Contact:
Jane Sparango
Coterie Media (for Renuvion)
jane@coteriemedia.com
310-339-1214
Investor Relations Contact:
ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/apyx-medical-corporation-launches-new-apyx-one-console-for-cosmetic-surgical-procedures-in-the-united-states-301730059.html
SOURCE Renuvion